The ability to measure binding affinity and drug-target residence time provides crucial information during the drug discovery process

In this short video, Dr Gary Allenby (Chief Scientific Officer at Aurelia Bioscience Ltd) talks about his experience with Promega’s NanoBRET™ Target Engagement (TE) Intracellular Kinase Assay. By employing this live-cell energy transfer technology and 3D micro-scaffolds, we are able to perform quantitative analysis of intracellular kinase target engagement under more physiologically relevant conditions.

Share This